271 related articles for article (PubMed ID: 30457413)
1. Tocilizumab for the Management of Corticosteroid-Resistant Mild to Severe Graves' Ophthalmopathy, a Report of Three Cases.
Maldiney T; Deschasse C; Bielefeld P
Ocul Immunol Inflamm; 2020; 28(2):281-284. PubMed ID: 30457413
[No Abstract] [Full Text] [Related]
2. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
Wiersinga WM
Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
[TBL] [Abstract][Full Text] [Related]
3. Response to tocilizumab treatment in Graves' ophthalmopathy by measuring rectus muscle thickness and chemosis using optical coherence tomography.
de-Pablo-Gómez-de-Liaño L; Fernández-Vigo JI; Troyano-Rivas J; Niño-Rueda C; Romo-López Á; Gómez-de-Liaño R
Arch Soc Esp Oftalmol (Engl Ed); 2018 Aug; 93(8):386-391. PubMed ID: 29937157
[TBL] [Abstract][Full Text] [Related]
4. Treatment of active corticosteroid-resistant graves' orbitopathy.
Pérez-Moreiras JV; Alvarez-López A; Gómez EC
Ophthalmic Plast Reconstr Surg; 2014; 30(2):162-7. PubMed ID: 24503568
[TBL] [Abstract][Full Text] [Related]
5. Success Treatment of Severe and Active Graves' Orbitopathy with Tocilizumab After Thyroidectomy and Maximum Dose of Intravenous Methylprednisolone.
Pramono LA
Acta Med Indones; 2023 Oct; 55(4):475-477. PubMed ID: 38213047
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial.
Perez-Moreiras JV; Gomez-Reino JJ; Maneiro JR; Perez-Pampin E; Romo Lopez A; Rodríguez Alvarez FM; Castillo Laguarta JM; Del Estad Cabello A; Gessa Sorroche M; España Gregori E; Sales-Sanz M;
Am J Ophthalmol; 2018 Nov; 195():181-190. PubMed ID: 30081019
[TBL] [Abstract][Full Text] [Related]
7. Successful Treatment for Severe Thyroid-associated Ophthalmopathy with Tocilizumab.
Canas CA; Bonilla-Abadia F; Vallejo K; Rengifo HM; Gallon MA; Tobon GJ
Endocr Metab Immune Disord Drug Targets; 2018; 18(6):665-667. PubMed ID: 29962351
[TBL] [Abstract][Full Text] [Related]
8. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy.
De Bellis A; Bizzarro A; Conte M; Coronella C; Solimeno S; Perrino S; Sansone D; Guaglione M; Wall JR; Bellastella A
Clin Endocrinol (Oxf); 2003 Sep; 59(3):388-95. PubMed ID: 12919164
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab versus Rituximab in Patients with Moderate to Severe Steroid-resistant Graves' Orbitopathy.
Bennedjaï A; Bouheraoua N; Gatfossé M; Dupasquier-Fediaevsky L; Errera MH; Tazartes M; Borderie V; Hennocq Q; Dellal A; Riviere S; Heron E; Fain O; Mekinian A
Ocul Immunol Inflamm; 2022 Feb; 30(2):500-505. PubMed ID: 32965148
[TBL] [Abstract][Full Text] [Related]
10. How suitable is intravenous tocilizumab for the treatment of Graves' ophthalmopathy?
Mejía González MA; Carbone J
Expert Rev Clin Immunol; 2021 Nov; 17(11):1151-1153. PubMed ID: 34704876
[No Abstract] [Full Text] [Related]
11. Tocilizumab in glucocorticoid-resistant graves orbitopathy. A case series report of a mexican population.
Ceballos-Macías José J; Rivera-Moscoso R; Flores-Real Jorge A; Vargas-Sánchez J; Ortega-Gutiérrez G; Madriz-Prado R; Velasco-Ramos PC; Muñoz-Monroy Omar E; Meneses-Pérez Anna C; Fernández-Morales Irma N; Hernández-Moreno A
Ann Endocrinol (Paris); 2020 Jun; 81(2-3):78-82. PubMed ID: 32340849
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous Tocilizumab for Thyroid Eye Disease: Simplified Dosing and Delivery.
Copperman T; Idowu OO; Kersten RC; Vagefi MR
Ophthalmic Plast Reconstr Surg; 2019; 35(3):e64-e66. PubMed ID: 30865069
[TBL] [Abstract][Full Text] [Related]
13. The effects of Rituximab on Graves'orbitopathy: A retrospective study of 14 patients.
Eid L; Coste-Verdier V; Longueville E; Ribeiro E; Nicolescu-Catargi B; Korobelnik JF
Eur J Ophthalmol; 2020 Sep; 30(5):1008-1013. PubMed ID: 31025590
[TBL] [Abstract][Full Text] [Related]
14. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
[TBL] [Abstract][Full Text] [Related]
15. Improvement of the MRI and clinical features of Asian Graves' ophthalmopathy by radiation therapy with steroids.
Ma Z; Ozaki H; Ishikawa Y; Jingu K
Jpn J Radiol; 2019 Aug; 37(8):612-618. PubMed ID: 31201593
[TBL] [Abstract][Full Text] [Related]
16. Clinical Response to Tocilizumab in Severe Thyroid Eye Disease.
Sy A; Eliasieh K; Silkiss RZ
Ophthalmic Plast Reconstr Surg; 2017; 33(3):e55-e57. PubMed ID: 27281483
[TBL] [Abstract][Full Text] [Related]
17. Intravenous cyclophosphamide pulse therapy is effective for refractory Graves' ophthalmopathy.
Tanikawa T; Okada Y; Tanaka Y
J UOEH; 2006 Jun; 28(2):185-91. PubMed ID: 16780226
[TBL] [Abstract][Full Text] [Related]
18. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
[TBL] [Abstract][Full Text] [Related]
19. Clinical Features of Graves' Ophthalmopathy and Impact of Enalapril on the Course of Mild Graves' Ophthalmopathy: A Pilot Study.
Ataabadi G; Dabbaghmanesh MH; Owji N; Bakhshayeshkaram M; Montazeri-Najafabady N
Endocr Metab Immune Disord Drug Targets; 2020; 20(1):139-148. PubMed ID: 31345156
[TBL] [Abstract][Full Text] [Related]
20. Three dimensional orbital magnetic resonance T2-mapping in the evaluation of patients with Graves' ophthalmopathy.
Hou K; Ai T; Hu WK; Luo B; Wu YP; Liu R
J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):938-942. PubMed ID: 29270757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
